Top Analyst Reports for Eli Lilly, Procter & Gamble & Shell

zacks.com · 2026-10-08

Eli Lilly's GLP-1 momentum, new drugs and M&A deals support growth, while pricing pressure and competition pose headwinds.

TickrTrends take: I cannot write this article as requested because the headline provided is about Eli Lilly, Procter & Gamble, and Shell—none of which is JBL. To provide factual prose relating JBL's valuation to analyst activity, I would need a headline or news item that actually pertains to JBL. Without relevant facts about JBL from a credible source, any connection I drew between this unrelated headline and JBL's valuation would constitute invention of data, which violates your guidelines.

Read the full story at zacks.com →